| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 09/14/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 08/10/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 07/21/2023 | 1134.57% | Piper Sandler | $13 → $20 | Maintains | Overweight |
| 07/05/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 05/23/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 05/10/2023 | 1072.84% | RBC Capital | → $19 | Reiterates | → Outperform |
| 04/11/2023 | 702.47% | Piper Sandler | $9 → $13 | Maintains | Overweight |
| 03/10/2023 | 1072.84% | RBC Capital | → $19 | Reiterates | → Outperform |
| 03/10/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 03/06/2023 | 455.56% | Roth MKM | → $9 | Reinstates | → Buy |
| 03/02/2023 | 1072.84% | RBC Capital | $20 → $19 | Maintains | Outperform |
| 02/07/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 08/16/2022 | 764.2% | Piper Sandler | $11 → $14 | Maintains | Overweight |
| 07/21/2022 | 2060.49% | HC Wainwright & Co. | $11 → $35 | Maintains | Buy |
| 05/18/2022 | 579.01% | Piper Sandler | $19 → $11 | Maintains | Overweight |
| 05/10/2022 | 1134.57% | RBC Capital | $22 → $20 | Maintains | Outperform |
| 11/11/2021 | 579.01% | HC Wainwright & Co. | $18 → $11 | Maintains | Buy |
| 10/12/2021 | 1258.02% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 09/21/2021 | 1072.84% | Piper Sandler | → $19 | Initiates Coverage On | → Overweight |
| 09/14/2021 | 1196.3% | Roth Capital | $20 → $21 | Maintains | Buy |
| 09/14/2021 | 1134.57% | Oppenheimer | $14 → $20 | Maintains | Outperform |
| 09/13/2021 | 1011.11% | HC Wainwright & Co. | $13 → $18 | Maintains | Buy |
| 05/18/2021 | 825.93% | JonesTrading | → $15 | Initiates Coverage On | → Buy |
| 03/24/2021 | 764.2% | Oppenheimer | $12 → $14 | Maintains | Outperform |
| 03/16/2021 | 1134.57% | Roth Capital | $15 → $20 | Maintains | Buy |
| 08/17/2020 | 702.47% | HC Wainwright & Co. | → $13 | Upgrades | Neutral → Buy |
| 03/27/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 03/02/2020 | 393.83% | Oppenheimer | → $8 | Initiates Coverage On | → Outperform |
| 11/05/2019 | 393.83% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
What is the target price for aTyr Pharma (LIFE)?
The latest price target for aTyr Pharma (NASDAQ: LIFE) was reported by HC Wainwright & Co. on September 21, 2023. The analyst firm set a price target for $35.00 expecting LIFE to rise to within 12 months (a possible 2060.49% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for aTyr Pharma (LIFE)?
The latest analyst rating for aTyr Pharma (NASDAQ: LIFE) was provided by HC Wainwright & Co., and aTyr Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for aTyr Pharma (LIFE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of aTyr Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for aTyr Pharma was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
Is the Analyst Rating aTyr Pharma (LIFE) correct?
While ratings are subjective and will change, the latest aTyr Pharma (LIFE) rating was a reiterated with a price target of $0.00 to $35.00. The current price aTyr Pharma (LIFE) is trading at is $1.62, which is within the analyst's predicted range.